肝肾综合征|肝肾综合征的治疗进展( 五 )


[13]WANG L, LONG Y, LI KX, et al. Pharmacological treatment of hepatorenal syndrome: A network meta-analysis[J]. Gastroenterol Rep (Oxf), 2020, 8(2): 111-118.
[14]CELIS P, RADA G. Noradrenaline or terlipressin for hepatorenal syndrome?[J]. Medwave, 2015, 15(Suppl 2): e6235.
[15]MATTOS Z, MATTOS AA, RIBEIRO RA. Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: Systematic review with meta-analysis and full economic evaluation[J]. Eur J Gastroenterol Hepatol, 2016, 28(3): 345-351.
[16]ZHANG Z, MADDUKURI G, JAIPAUL N, et al. Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin[J]. J Crit Care, 2015, 30(5): 969-974.
[17]PARK GC, HWANG S, JUNG DH, et al. Is renal replacement therapy necessary in deceased donor liver transplantation candidates with hepatorenal syndrome: A 2-year experience at a high-volume center[J]. Ann Surg Treat Res, 2020, 98(2): 102-109.
[18]KADE G, LUBAS A, SPALENIAK S, et al. Application of the molecular adsorbent recirculating system in type 1 hepatorenal syndrome in the course of alcohol-related acute on chronic liver failure[J]. Med Sci Monit, 2020, 26: e923805.
[19]LAVAYSSIRE L, KALLAB S, CARDEAU-DESANGLES I, et al. Impact of molecular adsorbent recirculating system on renal recovery in type-1 hepatorenal syndrome patients with chronic liver failure[J]. J Gastroenterol Hepatol, 2013, 28(6): 1019-1024.
[20]CHMIELEWSKI J, LEWANDOWSKI RJ, MADDUR H. Hepatorenal syndrome: Physiology, diagnosis and management[J]. Semin Intervent Radiol, 2018, 35(3): 194-197.
[21]SONG T, RSSLE M, HE F, et al. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis[J]. Dig Liver Dis, 2018, 50(4): 323-330.
[22]CHARILAOU P, DEVANI K, PETROSYAN R, et al. Inpatient mortality benefit with transjugular intrahepatic portosystemic shunt for hospitalized hepatorenal syndrome patients[J]. Dig Dis Sci, 2020. [Online ahead of print]
[23]TRIVEDI PS, BROWN MA, ROCHON PJ, et al. Gender disparity in inpatient mortality after transjugular intrahepatic portosystemic shunt creation in patients admitted with hepatorenal syndrome: A nationwide study[J]. J Am Coll Radiol, 2020, 17(2): 231-237.
[24]UTAKO P, EMYOO T, ANOTHAISINTAWEE T, et al. Clinical outcomes after liver transplantation for hepatorenal syndrome: A systematic review and meta-analysis[J]. Biomed Res Int, 2018, 2018: 5362810.
[25]OKAMURA Y, HATA K, INAMOTO O, et al. Influence of hepatorenal syndrome on outcome of living donor liver transplantation: A single-center experience in 357 patients[J]. Hepatol Res, 2017, 47(5): 425-434.
[26]FORMICA RN, AEDER M, BOYLE G, et al. Simultaneous liver-kidney allocation policy: A proposal to optimize appropriate utilization of scarce resources[J]. Am J Transplant, 2016, 16(3): 758-766.
[27]TARIQ R, SINGAL AK. Management of hepatorenal syndrome: A review[J]. J Clin Transl Hepatol, 2020, 8(2): 192-199.
[28]OJEDA-YUREN AS, CERDA-REYES E, HERRERO-MACEDA MR, et al. An integrated review of the hepatorenal syndrome[J]. Ann Hepatol, 2020. [Online ahead of print]
引证本文:李妍, 陆伦根, 蔡晓波. 肝肾综合征的治疗进展[J]. 临床肝胆病杂志, 2020, 36(11): 2415-2418.
作者:临床肝胆病杂志
【肝肾综合征|肝肾综合征的治疗进展】来源:临床肝胆病杂志

推荐阅读